Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2005
11/30/2005EP1259485B1 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP0963200B9 Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid
11/30/2005EP0951470B1 Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
11/30/2005CN1703405A Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1229646C Catalytic anti-factor VIII allo-antibodies
11/30/2005CN1229388C N-terminal modified protein compositions and methods therefor
11/30/2005CN1229385C Composition for stimulating megacaryocyte growth and differentiation and process thereof
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229113C A Pharmaceutical composition for the treatment of autoimmune diseases
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969720 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk (cyclin dependent kinases) complexes
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969715 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
11/24/2005WO2005111083A2 Antibodies specific for glycoprotein vi and methods of producing these antibodies
11/24/2005WO2005110383A1 The use of kauranes compounds in the manufacture of medicament
11/24/2005US20050261472 Binding moieties for fibrin
11/24/2005US20050261346 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo
11/24/2005US20050261343 Anthranilamides and their use as pharmaceutical agents
11/24/2005US20050261323 Medical uses of novel carbamate-substituted pyrazolopyridine derivatives
11/24/2005US20050261317 Inhibitors of human phosphatidylinositol 3-kinase delta
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261283 Methods and compositions for the treatment of graft failure
11/24/2005US20050261281 Pharmaceutical compounds
11/24/2005US20050261244 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
11/24/2005US20050261187 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy
11/24/2005US20050261169 Peptide and peptide mimetic derivatives having integrin inhibitor properties III
11/24/2005US20050261163 Pharmaceutical products, preparation and uses thereof
11/24/2005US20050260565 contacting in vitro a sample comprising chemokine 88C receptor with a putative ligand, detecting binding of the 88C receptor and the putative ligand; increase in 88C signal transduction activity indicates the ligand is an activator, a decreasein transduction activity indicates the ligand is an inhibitor
11/24/2005US20050260289 extracts from Lightyellow Sophora Root, Turmeric, Magnolia Bark, Moutan Bark extract, Isatis Leaf, Borneo Camphor Tree, Amur Cork Tree, Angelicae Dahuricae Root, Lemon, Smartweed extract, Licorice, Cnidii Rhizoma, Japanese Angelica Root extract, salicylic acid, resorcinol, alcohol, and water; eczema
11/24/2005US20050260154 G-CSF analog compositions and methods
11/24/2005CA2606472A1 The use of kauranes compounds in the manufacture of medicament
11/24/2005CA2565186A1 Substituted thiophen-carboxylic acid amides, the production and the use thereof in the form of a drug
11/24/2005CA2565063A1 Glycoprotein vi antibodies and method thereof
11/24/2005CA2564207A1 Novel substituted thiophenecarboxamides, their production and their use as medicaments
11/24/2005CA2562714A1 Substituted thiophene-2-carboxylic acid amides, the production thereof and the use thereof as drugs
11/24/2005CA2508065A1 Antiproliferative drug and delivery device
11/24/2005CA2507712A1 Pharmaceutical compounds
11/24/2005CA2507710A1 Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators
11/23/2005EP1598368A1 Anti-pci neutralizing antibody
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598076A1 Interleukin 6 production inhibitor
11/23/2005EP1597587A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
11/23/2005EP1597244A1 Ethynyl derivatives serving as factor xa inhibitors
11/23/2005EP1596854A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
11/23/2005EP1596850A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
11/23/2005EP1596804A2 SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF
11/23/2005EP1377550B9 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/23/2005EP1276497B1 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors
11/23/2005EP1194161B1 Stable factor viii compositions
11/23/2005EP1133555B1 Pharmaceutical factor vii preparation
11/23/2005EP1102601B1 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
11/23/2005EP0770129B1 Zinc finger protein derivatives and methods therefor
11/23/2005CN1701117A Antibody against enzyme specifically cleaving VON WILLEBRAND factor and assay system using the same
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700934A Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
11/23/2005CN1228078C Medicine composition for treating hematopiesis and its use
11/23/2005CN1228057C Compound of solanesol and its preparing process
11/23/2005CN1228049C Slow releasing micropill containing active component of indapamide and method for preparing the same
11/22/2005US6967239 obtaining a starting factor VIII solution comprising factor VIII-von Willebrand factor complexes; and filtering in presence of calcium chloride ions through hydrophilic virus filter having a mean pore size of 13 to 17 nm
11/22/2005US6967204 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005US6967020 Oxygen carrier system, artificial oxygen carrier, and reducing agent
11/22/2005CA2251558C Highly purified factor viii complex
11/17/2005WO2005107784A1 Remedy for thrombopenia
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005WO1997049725A9 Modified factor viii
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256304 Modified factor VIII
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256211 Patient oxygenation using stabilized fluorocarbon emulsions
11/17/2005US20050256141 Remedies for glomerular diseases
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256090 Comprises as an active ingredient a sulphostin-related compound such as 3(S)-amino-1-((S)-amino(sulfoamino)-phosphinyl)-2-piperidone
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256038 Stable pharmaceutical compsition containing factor VIII
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255470 determining the GPVI allelotype of subjects in need of surgery, with a low platelet count, with an acquired bleeding disorder, on blood thinning drugs, or of blood donors; diagnosis of an increased risk of bleeding
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255096 Combination treatment for acute myocardial infarction
11/17/2005US20050255076 Therapeutic cream for dermatitis
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2564033A1 A method for the prevention of thromboembolic disorders
11/17/2005CA2561141A1 Methods for treating blood disorders with nitric oxide donor compounds
11/16/2005EP1595539A1 Drug for reducing side effects in ribavirin interferon combination therapy
11/16/2005EP1595536A1 Pharmaceuticals comprising shikonins as active constituent
11/16/2005EP1594527A2 Vegf-b and pdgf modulation of stem cells
11/16/2005EP1594503A2 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
11/16/2005EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha
11/16/2005EP1476429B1 Novel pyridine- and quinoline-derivatives
11/16/2005EP1463823A4 Methods of increasing endogenous erythropoietin (epo)
11/16/2005EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors
11/16/2005EP1379516B1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists
11/16/2005EP1368419B1 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
1 ... 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 ... 671